相关临床试验
299
78 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2000
进行中（未招募）
75
25.1%
已完成
170
56.9%
Enrolling By Invitation
1
0.3%
尚未招募
2
0.7%
招募中
25
8.4%
暂停
2
0.7%
终止
8
2.7%
Unknown
10
3.3%
撤回
6
2.0%
暂无批准数据
- The STAMINA lifestyle intervention reduced deterioration in quality of life by as much as one-third in men receiving androgen deprivation therapy for prostate cancer, researchers reported in The Lancet Oncology. - In the 700-patient UK trial across 15 NHS hospitals, more than 80% of participants attended scheduled supervised exercise sessions over the 12-month study period. - Economic modelling showed the program costs well below standard NHS thresholds for cancer interventions and is expected to remain cost-effective for up to a decade. - Nuffield Health has launched a Cancer Activity Programme based on STAMINA, committing to fund 50,000 places by 2030 with planned expansion to breast and bowel cancer.
- The National Institute for Health and Care Research has launched the UK's first Parkinson's Disease Translational Research Collaboration, bringing together 17 centers of excellence to accelerate treatment and diagnostic development. - The collaboration addresses critical gaps in experimental medicine and early clinical trials for Parkinson's disease, which affects over 166,000 people in the UK. - Led by Professor Oliver Bandmann at Sheffield Teaching Hospitals, the initiative aims to bridge the gap between laboratory discoveries and patient benefits through coordinated translational research. - The PD-TRC represents the eighth NIHR Translational Research Collaboration and will foster partnerships between academia, NHS services, industry, and patient organizations to reduce research inequalities across the UK.
- The phase II DISCUS trial demonstrated that three cycles of chemotherapy followed by avelumab maintenance therapy achieved equivalent survival outcomes to six cycles in 267 patients with advanced bladder cancer. - Patients receiving the reduced three-cycle regimen reported maintained quality of life and experienced fewer severe side effects compared to those receiving six cycles of chemotherapy. - NHS guidelines have been updated to offer eligible patients a choice between three and six chemotherapy cycles followed by avelumab maintenance, potentially benefiting hundreds of patients annually.
- The £2 million Triceps trial has recruited 200 of its target 270 patients to test transcutaneous vagus nerve stimulation (TVNS) for post-stroke arm and hand weakness recovery. - The non-invasive treatment uses a wearable device with earpiece to deliver electrical pulses to the vagus nerve during home-based rehabilitation therapy. - Around one-third of stroke survivors experience permanent arm and hand weakness, making this potential treatment significant for improving independence and quality of life. - The double-blind trial expanded from 243 to 270 patients following interim analysis and needs just 65 more participants to complete recruitment across 19 NHS centers.
- The UK DANTE phase III trial found that 80.2% of patients who stopped immunotherapy after 12 months maintained disease control, compared to 87.6% who continued treatment for two years or more. - The study represents the largest prospective trial to date evaluating optimal treatment duration for inoperable late-stage melanoma with immunotherapy drugs like pembrolizumab and nivolumab. - While promising, the trial was underpowered due to pandemic-related recruitment challenges, meaning two-year treatment should remain the current standard. - Quality of life analyses showed little difference between shorter and longer treatment durations, with cost-effectiveness studies currently underway.
- A 24-year-old woman from York has become one of the first patients worldwide to participate in the FORTITUDE trial, a pioneering gene therapy study for facioscapulohumeral muscular dystrophy (FSHD). - The therapy, developed by Avidity Biosciences, targets the DUX4 gene that triggers muscle weakness and degeneration in FSHD patients, aiming to silence the gene and disrupt disease progression. - Preliminary data from the first phase showed unprecedented and consistent reduction of DUX4 regulated genes at four months, along with indications of functional improvement. - Sheffield Teaching Hospitals NHS Foundation Trust is one of only two non-American centers and the only UK site in Northern England recruiting patients for this landmark first-in-human trial.
• A new Phase 3 trial called FINESSE will evaluate whether finasteride can improve adherence to active surveillance in men with low and intermediate-risk prostate cancer. • The study will enroll 550 men across eight sites, randomizing patients to receive either standard active surveillance alone or with daily finasteride for two years. • The trial aims to address poor long-term compliance with active surveillance, with outcomes tracked for up to 10 years including disease progression, mortality, and quality of life measures.
- The TRICEPS trial is evaluating a portable device that uses electrical pulses to stimulate the vagus nerve via an earpiece, aiming to improve arm function in stroke patients. - The non-invasive treatment allows patients to undergo therapy at home while performing exercises, with researchers monitoring progress through bi-weekly video calls. - The trial, involving 240 patients across England and Wales, builds on previous studies suggesting nerve stimulation can restore electrical signals and reduce arm weakness. - Early participants in the trial have reported increased movement and improved function, offering hope for enhanced independence and quality of life for stroke survivors.
- An electronic tool, the stroke trial tracker, has been developed to streamline the screening and management of stroke patients for clinical trial eligibility. - The implementation of the tool has reduced screening time by over 80%, freeing up nurses' time for recruitment activities and increasing patient involvement in trials. - The electronic system minimizes human error, enhances efficiency, prevents redundant patient approaches, and improves overall team communication and data accuracy. - A survey of UK stroke centers indicates a strong interest in adopting similar systems to save time and improve the accuracy of patient screening for research studies.
